Pipeline
| NAME | ORIGINATOR | INDICATION | DEVELOPMENT STATUS |
|---|---|---|---|
| Urorec® / Silodyx® | Kissei | Benign prostatic hyperplasia (BPH) | Approved |
| Carbaglu® | Orphan Europe (Recordati) | NAGS deficiency | Approved in EU and in the U.S. |
| lercanidipine 8/16 mg | Pharmathen | Essential hypertension | Approved |
| Livazo®/Alipza® | Kowa | Dyslipidemia | Approved |
| Carbaglu® | Orphan Europe (Recordati) | Organic acidemias (OA) | Pre-registration in EU |
| Normosang® | Orphan Europe (Recordati) | Hepatic porphyria | Approved in EU Pre-registration in U.S. |
| Cystagon® | Mylan | Other indication unrelated to nephropathic cystinosis | Phase II-III |
| new lercanidipine combinations | Recordati | Essential hypertension | Phase II |
| Cystadrops® | Orphan Europe (Recordati) | Ocular cystinosis | Phase II |
| REC 0422 | Recordati | Overactive bladder and incontinence | Phase I-II |
| REC 1819 | Recordati | Overactive bladder and incontinence | Preclinical |
| REC 0436 | Recordati/UFPeptides | Overactive bladder in patients with spinal lesions | Preclinical |
